Beijing Ditan Hospital

Running trials

• Not yet recruiting

  ACT201 Injection in Participants With Chronic Hepatitis B (CHB) on Nucleos(t)Ide Analog Therapy - Phase Ib

  NCT07929805· Phase 1· Xiamen Amoytop Biotech Co., Ltd.· Source

• Not yet recruiting

  Clinical Trial of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogues(NAs) Versus NAs Alone for the Treatment of Patients With Chronic Hepatitis B Virus Infection Who Have Undergone Treatment and Exhibit Low Viral Load or Poor Response

  NCT07797231· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Not yet recruiting

  Study on Clinical and Pathological Features of Primary Biliary Cholangitis and Risk Factors Related to Disease Progression

  NCT07733882· Beijing Municipal Administration of Hospitals· Source

• Not yet recruiting

  Study on Clinicopathological Features, Influencing Factors and Clinical Outcomes in Patients With PSVD

  NCT07744048· Beijing Municipal Administration of Hospitals· Source

• Not yet recruiting

  A Study on the Consistency Evaluation of Digital PCR Technology for Quantitative Detection of HBV Nucleic Acid

  NCT07684209· Beijing Municipal Administration of Hospitals· Source

• Recruiting

  InstaSure™ Non-Invasive Finger-Press Test for Hepatocellular Carcinoma

  NCT07848750· Beijing Municipal Administration of Hospitals· Source

• Active, not recruiting

  A Clinical Study of HT-101 and HT-102 in Patients With Chronic Hepatitis B Virus Infection

  NCT07245953· Phase 2· Suzhou HepaThera Biotech Co., Ltd.· Source

• Recruiting

  A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

  NCT07165028· Phase 3· Eli Lilly and Company· Source

• Not yet recruiting

  CPET-based HIIT for MAFLD

  NCT07177963· Tang Yida· Source

• Not yet recruiting

  Phrenic Nerve Stimulation for Reducing Ventilation Duration in Acute Cerebral Infarction: A Multicenter Randomized Controlled Trial

  NCT07133932· Xuanwu Hospital, Beijing· Source

• Recruiting

  Sequential PEG-IFN for HBV After Ending RNA-targeted Regimens

  NCT06923280· Huashan Hospital· Source

• Not yet recruiting

  Prognostic Model for MASLD Related Cirrhosis

  NCT07082751· Beijing Friendship Hospital· Source

• Not yet recruiting

  A Study to Predict Recompensation in Patients With Decompensated Cirrhosis Using Spleen Stiffness and Simple Blood Tests

  NCT07087041· Beijing Friendship Hospital· Source

• Not yet recruiting

  Real-world Study on Liver Cancer Risk in Chronic Hepatitis B Patients With Family History of Liver Cancer

  NCT07007286· Peking University First Hospital· Source

• Active, not recruiting

  A Phase 1b Study of GKL-006 Injection in Patients With Unresectable Hepatocellular Carcinoma

  NCT07713290· Phase 1· Beijing Gene Key Life Technology Co., Ltd· Source

• Not yet recruiting

  The Efficacy and Safety of Chiglitazar in Patients with MAFLD-related Cirrhosis

  NCT06773221· Beijing Friendship Hospital· Source

• Active, not recruiting

  A Clinical Study of HT-101 and/or HT-102 in Patients With Chronic Hepatitis B Virus Infection

  NCT07183306· Phase 1/2· Suzhou HepaThera Biotech Co., Ltd.· Source

• Recruiting

  LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

  NCT06632457· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Research on Clinical Recovery and Maintenance Strategies for CHB

  NCT06803368· Beijing Municipal Administration of Hospitals· Source

• Recruiting

  LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

  NCT06632444· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Establishment of Precise Histological Evaluation Criteria for NASH Fibrosis Reversal

  NCT06707129· Beijing Municipal Administration of Hospitals· Source

• Recruiting

  Exploring the Genome-wide Association Study of the Population With Clinical Cure Advantage in the Treatment of Chronic Hepatitis B With Long-acting Interferon

  NCT06696664· Minghui Li· Source

• Enrolling by invitation

  Clinical Study of Antiviral Therapy Combined With Novel Immunotherapy for CHB in Adults

  NCT06777173· Beijing Ditan Hospital· Source

• Recruiting

  Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

  NCT06051617· Phase 3· Gilead Sciences· Source

• Recruiting

  Hydronidone Capsules in Long-term Treatment in Patients With Chronic Viral Hepatitis B Liver Fibrosis

  NCT05905172· Phase 3· Beijing Continent Pharmaceutical Co, Ltd.· Source

• Active, not recruiting

  A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

  NCT04849728· Phase 3· Inventiva Pharma· Source

• Recruiting

  Regression of Liver Fibrosis by Tenofovir Alafenamide (TAF)

  NCT04939441· Phase 4· Jidong Jia· Source

• Active, not recruiting

  A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)

  NCT04344158· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Active, not recruiting

  Prediction System of Clinical Endpoint Events for Chronic Hepatitis B Patients

  NCT03777969· Beijing Friendship Hospital· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Hepatitis B12 recruiting
• Fatty liver disease (MASLD/MASH)8 recruiting
• Liver cirrhosis5 recruiting
• Liver and biliary tract cancer3 recruiting
• Primary biliary cholangitis2 recruiting
• High blood pressure1 recruiting
• Stroke1 recruiting

Closed trials

• Completed

  Food Effect and Multiple-Dose Study of Chiglitazar/Metformin Extended-Release Tablets

  NCT07511010· Phase 1· Chipscreen Biosciences, Ltd.· Source

• Completed

  Bioequivalence Study of Chiglitazar/Metformin Extended-Release Tablets

  NCT07519265· Chipscreen Biosciences, Ltd.· Source

• Completed

  Alcohol Consumption and Plasma cfDNA Methylation in Chronic Hepatitis B

  NCT07865520· Beijing Municipal Administration of Hospitals· Source

• Withdrawn

  A Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets in Treatment-naive Chronic HBV-infected Subjects

  NCT06990776· Phase 2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Completed

  Clinical Study of TQA3605 Tablets Combined With Nucleoside (Acid) Analogs (NAs) Drugs Compared With NAs Drugs in the Treatment of Chronic Hepatitis B Virus (HBV) Infection

  NCT06644417· Phase 2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Completed

  Phase Ib/IIa Clinical Study of ACC017 Tablets

  NCT06719310· Phase 1/2· Jiangsu Aidea Pharmaceutical Group Co., Ltd.· Source

• Completed

  The Safety and Tolerability of STSA-1301 Subcutaneous Injection in Healthy Subjects

  NCT06148389· Phase 1· Staidson (Beijing) Biopharmaceuticals Co., Ltd· Source

• Completed

  This is a Phase 1 Study in Which Healthy Volunteers and Participants With Chronic HBV Infection Will be Assessed for Safety, Tolerability, Pharmacokinetics (PK), and Antiviral Activity

  NCT06746311· Phase 1· Suzhou HepaThera Biotech Co., Ltd.· Source

• Completed

  A Study to Evaluate the Antiviral Activity and Safety of HH-003 in Chronic Hepatitis B Subjects With Low-level Viremia

  NCT05734807· Phase 2· Huahui Health· Source

• Completed

  Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Viral Hepatitis B Phase 3 Trial.

  NCT05115942· Phase 3· Beijing Continent Pharmaceutical Co, Ltd.· Source

• Completed

  Efficacy and Safety Study of Peginterferon Alfacon-2 to Treat Chronic Hepatitis B Virus Infection

  NCT06544551· Phase 3· Beijing Kawin Technology Share-Holding Co., Ltd.· Source

• Completed

  A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)

  NCT04771273· Phase 2· Boehringer Ingelheim· Source

• Completed

  A Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B

  NCT04846491· Phase 3· Xiamen Amoytop Biotech Co., Ltd.· Source

• Completed

  Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults

  NCT03547908· Phase 3· Gilead Sciences· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Hepatitis B20 works · 23 trials
• Liver cirrhosis8 works · 6 trials